Viewing nowLyrica Capsule 25 mg (Pregabalin)
Pregabalin 25mg
Hard capsule · Prescription medication
Viatriss Korea Co., Ltd.

MFDS item code 201800928 · Approved 2018.02.26 · Insurance code 073400230
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures in epilepsy
This medication is used to treat peripheral and central neuropathic pain in adults. It can also be used as an adjunct for partial seizures in epilepsy patients, with or without secondary generalized symptoms. Furthermore, it is effective in alleviating the symptoms of fibromyalgia. Therefore, this drug helps in the treatment of various nerve-related pain and epilepsy.
This medication is administered orally, with or without food, as the total daily dose of pregabalin divided into 2 doses. Because this medication is eliminated primarily by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with Renal Impairment’) 1. Neuropathic Pain 1) Peripheral Neuropathic Pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central Neuropathic Pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation’) 2. Epilepsy Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medication for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies were also conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of the dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation Based on current clinical experience, if treatment with this medication is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medication is eliminated primarily by the kidneys as unchanged drug. Because its clearance is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula: Creatinine clearance (mL/min)* = [140 – age (years)] x body weight (kg) 72 x serum creatinine concentration (mg/dL) * For women, multiply the result obtained using the above equation by 0.85. This medication is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1] Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) | Total daily dose of pregabalinᵃ Starting dose (mg/day) | Maximum dose (mg/day) | Dosing regimen ≥60 | 150 | 600 | BID or TID ≥30-<60 | 75 | 300 | BID or TID ≥15-<30 | 25-50 | 150 | QD or BID <15 | 25 | 75 | QD Supplemental dose after hemodialysis | 25 | 100 | Single doseᵇ TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily ᵃ: The total daily dose (mg/day) should be divided as specified under the dosing regimen. ᵇ: The supplemental dose refers to an additional dose administered once. 6. Patients with Hepatic Impairment Dose adjustment is not necessary in patients with hepatic impairment. 8. Older Adults (65 years and older) Dose reduction may be necessary in older adults with impaired renal function.
Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12-17 years: Administration is not recommended because there are insufficient data on safety and efficacy.
This medication may increase the risk of suicidal thoughts or behavior, so careful monitoring for signs of depression, mood changes, or abnormal behavior is necessary during treatment. Patients with an allergy to any of this medication's components or with congenital lactose intolerance should not take it. Diabetic patients should be cautious, as weight gain may necessitate adjustments in the dosage of blood glucose control drugs. If symptoms of hypersensitivity, such as angioedema occur, the medication should be discontinued immediately. Elderly patients should be especially cautious in the initial phases of treatment due to the possibility of dizziness, drowsiness, or altered consciousness. If visual disturbances or changes in vision occur, consult a healthcare professional. When discontinuing this medication, withdrawal symptoms such as insomnia, headache, and anxiety may appear. Therefore, the discontinuation should be done according to medical advice. Patients with a history of substance abuse may be at risk for misuse or abuse of this medication, so careful assessment before use is required. Patients with impaired kidney function may require dosage adjustments. Patients with heart conditions should exercise caution when taking this medication. Concomitant use with opioid analgesics may enhance central nervous system depressant effects, necessitating caution. Patients with respiratory or neurological conditions, as well as the elderly, are at risk for severe respiratory depression and should take this medication with caution. Pregnant women should avoid this medication during early pregnancy due to the potential effects on the fetus, and women of childbearing age should use effective contraception. Breastfeeding women are advised against taking this medication, as it can be passed into breast milk. Care should be taken when driving or operating machinery, as dizziness or drowsiness may occur after taking this medication. Severe skin reactions may rarely occur, and if symptoms such as skin rash or swelling arise, stop taking the medication and consult a healthcare professional immediately. Overdose may result in confusion, drowsiness, and depression, and may require treatments such as blood dialysis if necessary. Keep this medication out of the reach of children and do not transfer it to other containers.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to avoid exposure to air or moisture. It is important to maintain a storage temperature between 15°C and 30°C. This will help safely preserve the medication's efficacy.
A hard capsule with a white upper part and a white lower part containing a white or light yellow powder.
30 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 25mg
Hard capsule · Prescription medication
Viatriss Korea Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.